

DATE: _____ NEEDS BY DATE: _____
 SHIP TO: OFFICE

Patient Information

Patient Name	
Address	
City, State, Zip	
Main Phone	Alternate Phone
Social Security #	
Date of Birth	<input type="checkbox"/> Male <input type="checkbox"/> Female

Provider Information

Prescriber Name		
DEA #	NPI #	License #
Address		
City, State, Zip		
Phone	Fax	
Contact Person		

Clinical Information

Diagnosis:
 J45.40 Moderate Asthma J45.50 Severe Asthma
 L20.9 Atopic Dermatitis L50.1 Chronic Idiopathic Urticaria (CIU)
 Other: Dx code _____ Condition _____

Drug Allergies: _____
 Concomitant therapies:
 Short-acting beta agonist Long-acting beta agonist Antihistamines
 Decongestants Immunotherapy Inhaled corticosteroid
 Leukotriene modifiers Oral steroids Nasal steroids
 Other: _____

Please list therapies: _____

Lab results: History of positive skin OR RAST test to a perennial aeroallergen
 Pretreatment serum IgE level ____ IU per mL Test date _____
 Patient weight _____ kg Date weight obtained _____

MD Specialty:
 Allergist Pulmonologist ENT Primary Care Pediatrician
 Dermatologist Other: _____

Prescription type: Naïve/new start Restart Continued Therapy
 Last injection date: _____

Product	Quantity	Prescription Information	Supply	Refills
<input type="radio"/> Dupixent®	300mg/2mL PFS w/ shield	<input type="radio"/> Load: Inject 600mg (2-300mg injections in different injection sites) on Day 1, then 300mg on Day 15, then 300mg every other week. <input type="radio"/> Maintenance: Inject 300mg subcutaneously every other week	2 syringes 2 syringes	none _____
<input type="radio"/> Fasenra®		Please complete Fasenra Access 360 Enrollment Form and fax to Eventus Rx at 866-330-7487		
<input type="radio"/> Nucala® (Patients with Asthma)	Diluent: 1.2mL of sterile water for Injection, USP, preferably using a 2 or 3mL syringe and a 21-gauge needle. The reconstituted solution will contain a concentration of 100mg/mL mepolizumab.	Inject 100mg subcutaneously once every 4 weeks	28 day supply	_____
<input type="radio"/> Nucala® (Patients with EGPA)	Diluent: 1.2mL of sterile water for Injection, USP, preferably using a 2 or 3mL syringe and a 21-gauge needle. The reconstituted solution will contain a concentration of 100mg/mL mepolizumab.	Inject 300mg (3-100mg injections) subcutaneously once every 4 weeks	28 day supply	_____
<input type="radio"/> Xolair® (Patients with Allergic Asthma)	Diluent: 10mL vial preservative free sterile water for injection, USP; ancillary supplies: 3mL syringes as needed for reconstitution; 25-gauge needles as needed for administration.	<input type="radio"/> Inject 75mg subcutaneously once every 4 weeks <input type="radio"/> Inject 150mg subcutaneously once every 4 weeks <input type="radio"/> Inject 225mg subcutaneously once every 2 weeks <input type="radio"/> Inject 225mg subcutaneously once every 4 weeks <input type="radio"/> Inject 300mg subcutaneously once every 2 weeks <input type="radio"/> Inject 300mg subcutaneously once every 4 weeks <input type="radio"/> Inject 375mg subcutaneously once every 2 weeks	28 day supply	_____ _____
<input type="radio"/> Xolair® (Patients with CIU)	Diluent: 10-mL vial preservative free sterile water for injection, USP; ancillary supplies: 3mL syringes as needed for reconstitution; 25-gauge needles as needed for administration.	<input type="radio"/> Inject 150mg subcutaneously once every 4 weeks <input type="radio"/> Inject 300mg subcutaneously once every 4 weeks	28 day supply	_____ _____
<input type="radio"/> EpiPen®	<input type="radio"/> EpiPen®: Injection, 0.3mg; 0.3mg/0.3mL epinephrine, USP, pre-filled auto-injector <input type="radio"/> EpiPen Jr®: Injection, 0.15mg; 0.15mg/0.3mL epinephrine, USP, pre-filled auto-injector	Inject EpiPen® 0.3mg intramuscularly or subcutaneously in Patients greater than or equal to 30kg (66lbs) Inject EpiPen Jr® 0.15mg intramuscularly or subcutaneously in Patients 15 to 30kg (33lbs to 66lbs)	2 2	0 0
<input type="radio"/> Other				

PLEASE FAX COPY OF : 1) PRESCRIPTION CARD FRONT & BACK 2) CLINICAL NOTES 3) MEDICAL CARD FRONT & BACK

By signing this form and utilizing our services, you are authorizing Eventus Rx, Inc to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber's Signature (no stamps)

Date

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.